Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (11)

2023

  1. Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study

    Journal of Infection, Vol. 87, Núm. 1, pp. 46-53

  2. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations

    Microbiology spectrum, Vol. 11, Núm. 4, pp. e0067423

2022

  1. Resistance to empirical β-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: A multicentre study

    Journal of Antimicrobial Chemotherapy, Vol. 77, Núm. 7, pp. 2017-2023

2020

  1. Risk factors and outcome of COVID-19 in patients with hematological malignancies

    Experimental Hematology and Oncology, Vol. 9, Núm. 1

2014

  1. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

    Haematologica, Vol. 99, Núm. 10, pp. 1632-1637

2013

  1. Tratamiento de las infecciones fúngicas invasoras en pacientes hematológicos de alto riesgo: ¿Qué hemos aprendido en los pasados 10 años?

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 4, pp. 378-386

2011

  1. Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 6, pp. 435-454

  2. Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) guidelines for the diagnosis of invasive fungal infections. 2010 Update

    Enfermedades Infecciosas y Microbiologia Clinica

2008

  1. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain

    Medicina Clinica, Vol. 131, Núm. 12, pp. 441-446

  2. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study

    Haematologica, Vol. 93, Núm. 12, pp. 1829-1836

2001

  1. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease

    British Journal of Haematology, Vol. 113, Núm. 1, pp. 161-171